BIVI
BIOVIE INC.
NASDAQ · Healthcare · Biotechnology · US
$1.61
−9.55%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$1.80
From 52W high−29.39%
Volume403433.00
Market cap$13.74M
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataSep 18, 2026
Open
$1.80
From 52W high
−29.39%
Volume
403433.00
Market cap
$13.74M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−0.2x
P/E (TTM)
—
RSI (14)
45.9
MomentumView details →
1D Return
−9.55%
YTD Return
+48.47%
SummaryUpdated Jun 1, 2026
BioVie Inc. (NASDAQ:BIVI) is a clinical-stage biotechnology company founded in 2013 and based in Carson City, Nevada. Originally incorporated as NanoAntibiotics, Inc., the company rebranded to BioVie Inc. in July 2016 and went public in September 2020. BioVie focuses on discovering, developing, and commercializing novel drug therapies, with a particular emphasis on treatments for neurological disorders and liver diseases. The company operates as a pure-play research and development organization with no current revenue-generating products, as all of its therapeutic candidates remain in various stages of clinical trials.
Similar companies
Latest newsMore news →
BioVie announced topline results from its Phase 2 ADDRESS-LC trial evaluating bezisterim for treating neurological symptoms associated with Long COVID, reporting statistically significant benefits in pre-specified subgroups with high baseline fatigue, cognitive impairment, and/or post-exertional malaise.5d agoBioVie Inc requested an End-of-Phase 2 meeting with the US Food and Drug Administration to advance its Phase 3 development program for bezisterim in Parkinson's disease.12d agoBioVie Inc. completed the treatment phase of its ADDRESS-LC Phase 2 trial of bezisterim for neurological symptoms of Long COVID.20d ago